165 related articles for article (PubMed ID: 34635925)
41. Construction of a prognostic model based on memory CD4+ T cell-associated genes for lung adenocarcinoma and its applications in immunotherapy.
Li Y; Ye X; Huang H; Cao R; Huang F; Chen L
CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):837-852. PubMed ID: 38594917
[TBL] [Abstract][Full Text] [Related]
42. [Construction and Validation of Prognostic Risk Score Model of Autophagy Related Genes in Lung Adenocarcinoma].
Zhou J; Wang X; Li Z; Jiang R
Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):557-566. PubMed ID: 34256900
[TBL] [Abstract][Full Text] [Related]
43. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
[TBL] [Abstract][Full Text] [Related]
44. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
Front Genet; 2022; 13():1017866. PubMed ID: 36699466
[No Abstract] [Full Text] [Related]
45. Abnormal Expression and Prognostic Significance of Bone Morphogenetic Proteins and Their Receptors in Lung Adenocarcinoma.
Xu Z; Chen C
Biomed Res Int; 2021; 2021():6663990. PubMed ID: 34036102
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
47. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
Song Q; Shang J; Yang Z; Zhang L; Zhang C; Chen J; Wu X
J Transl Med; 2019 Mar; 17(1):70. PubMed ID: 30832680
[TBL] [Abstract][Full Text] [Related]
48. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
49. Multi-omics analysis of m
Wu X; Bai Z
Sci Rep; 2021 Oct; 11(1):20921. PubMed ID: 34686691
[TBL] [Abstract][Full Text] [Related]
50. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
Wang H; Wei C; Pan P; Yuan F; Cheng J
Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
[TBL] [Abstract][Full Text] [Related]
51. Prognostic Hub Genes in the Immune Microenvironment of Lung Adenocarcinoma by Estimation.
Liu S; Tian W; Li B
Comb Chem High Throughput Screen; 2022; 25(1):77-89. PubMed ID: 33308118
[TBL] [Abstract][Full Text] [Related]
52. Construction of an immune-related lncRNA pairs model to predict prognosis and immune landscape of lung adenocarcinoma patients.
Liu J; Wu H; Gao Z; Lou M; Yuan K
Bioengineered; 2021 Dec; 12(1):4123-4135. PubMed ID: 34288805
[TBL] [Abstract][Full Text] [Related]
53. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
54. A gene expression-based immune signature for lung adenocarcinoma prognosis.
Wang L; Luo X; Cheng C; Amos CI; Cai G; Xiao F
Cancer Immunol Immunother; 2020 Sep; 69(9):1881-1890. PubMed ID: 32372138
[TBL] [Abstract][Full Text] [Related]
55. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death.
Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J
Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954
[TBL] [Abstract][Full Text] [Related]
56. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
[TBL] [Abstract][Full Text] [Related]
57. AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma.
Zhang S; Lu Y; Qi L; Wang H; Wang Z; Cai Z
Biomed Res Int; 2020; 2020():8571932. PubMed ID: 32904605
[TBL] [Abstract][Full Text] [Related]
58. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
Tian WJ; Liu SS; Li BR
Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
[TBL] [Abstract][Full Text] [Related]
59. Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.
Bi G; Chen Z; Yang X; Liang J; Hu Z; Bian Y; Sui Q; Li R; Zhan C; Fan H
Cancer Immunol Immunother; 2020 Jul; 69(7):1293-1305. PubMed ID: 32189030
[TBL] [Abstract][Full Text] [Related]
60. High Expression of
Chen Y; Zhou M; Gu X; Wang L; Wang C
Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
